As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...

The local company announced Friday morning at 5:35 a.m. that it was withdrawing its bid to buy Evotec for about $11.52 per ...

Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to ...

Analysis of Halozyme Therapeutics, Inc.'s recent developments including revenue growth, patent expiration concerns, and new ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...

Shares of Halozyme Therapeutics (NASDAQ:HALO) added ~12% in the premarket on Friday after the drug delivery technology ...

Investing.com - Shares of Halozyme Therapeutics (NASDAQ:HALO) surged 12% at $51.2 before the opening bell on Friday after the ...

Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...

Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its ...

Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal that would ...